articleCirculationAug 10, 2004Closed access

Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy

Brigham and Women's Hospital · University Medical Center Groningen · +5 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

BACKGROUND: Albuminuria is an established risk marker for both cardiovascular and renal outcomes. Albuminuria can be reduced with drugs that block the renin-angiotensin system (RAS). We questioned whether the short-term drug-induced change in albuminuria would predict the long-term cardioprotective efficacy of RAS intervention. METHODS AND RESULTS: We analyzed data from Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL), a double-blind, randomized trial in 1513 type 2 diabetic patients with nephropathy, focusing on the relationship between the prespecified cardiovascular end point (composite) or hospitalization for heart failure and baseline…

Citation impact

751
total citations
FWCI
26.41
Percentile
100%
References
34
Citations per year

Authors

10

Topics & keywords

Keywords
  • Albuminuria
  • Medicine
  • Internal medicine
  • Diabetic nephropathy
  • Cardiology
  • Surrogate endpoint
  • Diabetes mellitus
  • Type 2 diabetes
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.